Alpha 2.0
Login Register
» Authors » Vicki L Nienaber

Vicki L Nienaber

Explore the profile of Vicki L Nienaber including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 110
Followers 0
Related Specialties
Biochemistry
Chemistry
Oncology
Top 10 Co-Authors
John Badger
Vandana Sridhar
Aulma R Parker
Michael D Wendt
Harry Kochat
Moshe Weitzberg
Cheyenne Logan
Vered Klinghofer
Philippe Y Ayala
Vincent L Giranda
Published In
J Med Chem
Onco Targets Ther
J Biol Chem
Molecules
Bioorg Med Chem Lett
Affiliations
Soon will be listed here.
Recent Articles
1.
Cysteine specific targeting of the functionally distinct peroxiredoxin and glutaredoxin proteins by the investigational disulfide BNP7787
Parker A, Petluru P, Nienaber V, Badger J, Leverett B, Jair K, et al.
Molecules . 2015 Mar; 20(3):4928-50. PMID: 25793542
Glutaredoxin (Grx), peroxiredoxin (Prx), and thioredoxin (Trx) are redoxin family proteins that catalyze different types of chemical reactions that impact cell growth and survival through functionally distinct intracellular pathways. Much...
2.
Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787
Parker A, Petluru P, Nienaber V, Zhao M, Ayala P, Badger J, et al.
Onco Targets Ther . 2015 Feb; 8:375-83. PMID: 25678804
BNP7787 (Tavocept, disodium 2,2'-dithio-bis-ethanesulfonate) is a novel, investigational, water-soluble disulfide that is well-tolerated and nontoxic. In separate randomized multicenter Phase II and Phase III clinical trials in non-small-cell lung cancer...
3.
Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties
Bruncko M, McClellan W, Wendt M, Sauer D, Geyer A, Dalton C, et al.
Bioorg Med Chem Lett . 2004 Dec; 15(1):93-8. PMID: 15582418
A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors.
4.
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase
Atwell S, Adams J, Badger J, Buchanan M, Feil I, Froning K, et al.
J Biol Chem . 2004 Oct; 279(53):55827-32. PMID: 15507431
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase required for signaling from immunoreceptors in various hematopoietic cells. Phosphorylation of two tyrosine residues in the activation loop of the Syk...
5.
Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization
Sanders W, Nienaber V, Lerner C, McCall J, Merrick S, Swanson S, et al.
J Med Chem . 2004 Mar; 47(7):1709-18. PMID: 15027862
Potent inhibitors of 7,8-dihydroneopterin aldolase (DHNA; EC 4.1.2.25) have been discovered using CrystaLEAD X-ray crystallographic high-throughput screening followed by structure-directed optimization. Screening of a 10 000 compound random library provided...
6.
Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution
Wendt M, Rockway T, Geyer A, McClellan W, Weitzberg M, Zhao X, et al.
J Med Chem . 2004 Jan; 47(2):303-24. PMID: 14711304
The preparation and assessment of biological activity of 6-substituted 2-naphthamidine inhibitors of the serine protease urokinase plasminogen activator (uPA, or urokinase) is described. 2-Naphthamidine was chosen as a starting point...